The hunt for a successor to lithium for bipolar disorder
Toxicity problems and adverse side effects when taking lithium, the mainstay medication for treating bipolar disorder, are fostering a scientific hunt for insights into exactly how lithium works in the body — with an eye to developing a safer alternative, published in the current edition of Chemical & Engineering News (C&EN).
Bethany Halford, C&EN senior editor, explains that lithium often is the first-line medication used to calm the highs and boost the lows of bipolar disorder, which affects about 9 million people at some point in their lives in the United States alone. Lithium has distinct advantages over the dozen or so other medications. For instance, lithium is the only medication proven effective in preventing suicide in the mania phase of bipolar disorder. Lithium also is inexpensive.
The article explains, however, that lithium also has drawbacks, with a fine line between the effective dose and the toxic dose. Side effects include thyroid problems, weight gain and, in some cases, kidney failure. In the hope of skirting lithium's limitations, scientists are trying to pinpoint exactly how lithium stabilizes mood and how it engenders those unwanted effects. The goal is development of a second-generation successor without lithium's downsides, and Halford describes how scientists are working to do so.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.